{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:33:25Z","timestamp":1793309605798,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Science and Technology Project of Traditional Chinese Medicine in Zhejiang Province","award":["2023ZL522"],"award-info":[{"award-number":["2023ZL522"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03756-8","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:40:57Z","timestamp":1741758057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The association between the dietary index for gut microbiota and non-alcoholic fatty liver disease and liver fibrosis: evidence from NHANES 2017\u20132020"],"prefix":"10.1186","volume":"25","author":[{"given":"Ce","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"3756_CR1","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction associated steatotic liver disease. Clin Mol Hepatol. 2024.","DOI":"10.1016\/j.metabol.2024.156004"},{"key":"3756_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/tgh-23-118","volume":"9","author":"X Dong","year":"2024","unstructured":"Dong X, Li J, Lu X, Lin X, Hong M, Weng S, Pan J. Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future. Translational Gastroenterol Hepatol. 2024;9:33.","journal-title":"Translational Gastroenterol Hepatol"},{"issue":"6","key":"3756_CR3","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, Joukar F, Habibi A, Javid M, Sattari N, Khorasani M, Farahmand A, Tavakoli S, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review Meta-Analysis comprising a population of 78 million from 38 countries. ARCH MED RES. 2024;55(6):103043.","journal-title":"ARCH MED RES"},{"issue":"10290","key":"3756_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"key":"3756_CR5","doi-asserted-by":"crossref","unstructured":"Calzadilla BL, Adams LA. The natural course of Non-Alcoholic fatty liver disease. Int J Mol Sci 2016;17(5).","DOI":"10.3390\/ijms17050774"},{"key":"3756_CR6","doi-asserted-by":"publisher","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","volume":"12","author":"J Fang","year":"2022","unstructured":"Fang J, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH, Yu WY. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. FRONT CELL INFECT MI. 2022;12:997018.","journal-title":"FRONT CELL INFECT MI"},{"key":"3756_CR7","doi-asserted-by":"publisher","first-page":"1257903","DOI":"10.3389\/fmicb.2023.1257903","volume":"14","author":"H Mai","year":"2023","unstructured":"Mai H, Yang X, Xie Y, Zhou J, Wang Q, Wei Y, Yang Y, Lu D, Ye L, Cui P, et al. The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease. Front Microbiol. 2023;14:1257903.","journal-title":"FRONT MICROBIOL"},{"issue":"1","key":"3756_CR8","doi-asserted-by":"publisher","first-page":"2078612","DOI":"10.1080\/19490976.2022.2078612","volume":"14","author":"H Kang","year":"2022","unstructured":"Kang H, You HJ, Lee G, Lee SH, Yoo T, Choi M, Joo SK, Park JH, Chang MS, Lee DH, et al. Interaction effect between NAFLD severity and high carbohydrate diet on gut Microbiome alteration and hepatic de Novo lipogenesis. Gut Microbes. 2022;14(1):2078612.","journal-title":"Gut Microbes"},{"key":"3756_CR9","doi-asserted-by":"crossref","unstructured":"Yang Q, Liang Q, Balakrishnan B, Belobrajdic DP, Feng QJ, Zhang W. Role of dietary nutrients in the modulation of gut microbiota: a narrative review. Nutrients 2020;12(2).","DOI":"10.3390\/nu12020381"},{"issue":"12","key":"3756_CR10","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1017\/S136898000900531X","volume":"12","author":"A Wirt","year":"2009","unstructured":"Wirt A, Collins CE. Diet quality\u2013what is it and does it matter? PUBLIC HEALTH NUTR. 2009;12(12):2473\u201392.","journal-title":"PUBLIC HEALTH NUTR"},{"key":"3756_CR11","doi-asserted-by":"crossref","unstructured":"Kase BE, Liese AD, Zhang J, Murphy EA, Zhao L, Steck SE. The development and evaluation of a literature-based dietary index for gut microbiota. Nutrients 2024;16(7).","DOI":"10.3390\/nu16071045"},{"issue":"3","key":"3756_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J HEPATOL. 2020;72(3):558\u201377.","journal-title":"J HEPATOL"},{"issue":"1","key":"3756_CR13","doi-asserted-by":"publisher","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","volume":"16","author":"R Bened\u00e9-Ubieto","year":"2024","unstructured":"Bened\u00e9-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated steatotic liver disease (MASLD). Gut Microbes. 2024;16(1):2331460.","journal-title":"Gut Microbes"},{"issue":"6","key":"3756_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis VER, et al. Accuracy of fibroscan controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"key":"3756_CR15","unstructured":"Team DC. DecisionLinnc. 1.0. In.; 2023."},{"key":"3756_CR16","doi-asserted-by":"crossref","unstructured":"Ji Y, Yin Y, Li Z, Zhang W. Gut microbiota-derived components and metabolites in the progression of. Nutrients 2019;11(8).","DOI":"10.3390\/nu11081712"},{"key":"3756_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.phrs.2019.01.029","volume":"141","author":"Y Ding","year":"2019","unstructured":"Ding Y, Yanagi K, Cheng C, Alaniz RC, Lee K, Jayaraman A. Interactions between gut microbiota and non-alcoholic liver disease: the role of. PHARMACOL RES. 2019;141:521\u20139.","journal-title":"PHARMACOL RES"},{"key":"3756_CR18","doi-asserted-by":"crossref","unstructured":"den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen AK, Reijngoud D et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPAR\u03b3-dependent switch from lipogenesis to fat oxidation. Diabetes 2015;64(7):2398\u20132408.","DOI":"10.2337\/db14-1213"},{"issue":"2","key":"3756_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/nutrit\/nuad042","volume":"82","author":"NHT Pham","year":"2024","unstructured":"Pham NHT, Joglekar MV, Wong WKM, Nassif NT, Simpson AM, Hardikar AA. Short-chain fatty acids and insulin sensitivity: a systematic review and. NUTR REV. 2024;82(2):193\u2013209.","journal-title":"NUTR REV"},{"issue":"5","key":"3756_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s00394-020-02431-w","volume":"60","author":"W Liu","year":"2021","unstructured":"Liu W, Luo X, Tang J, Mo Q, Zhong H, Zhang H, Feng F. A Bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier. EUR J NUTR. 2021;60(5):2317\u201330.","journal-title":"EUR J NUTR"},{"issue":"17","key":"3756_CR21","doi-asserted-by":"publisher","first-page":"e1900257","DOI":"10.1002\/mnfr.201900257","volume":"63","author":"X Tan","year":"2019","unstructured":"Tan X, Liu Y, Long J, Chen S, Liao G, Wu S, Li C, Wang L, Ling W, Zhu H. Trimethylamine N-Oxide aggravates liver steatosis through modulation of bile acid metabolism and Inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease. Mol Nutr Food Res. 2019;63(17):e1900257.","journal-title":"MOL NUTR FOOD RES"},{"issue":"1","key":"3756_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13643-023-02299-x","volume":"12","author":"A Naghipour","year":"2023","unstructured":"Naghipour A, Amini-Salehi E, Orang GM, Shahdkar M, Fouladi B, Alipourfard I, Sanat ZM. Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. SYST REV-LONDON. 2023;12(1):144.","journal-title":"SYST REV-LONDON"},{"issue":"8","key":"3756_CR23","doi-asserted-by":"publisher","first-page":"103110","DOI":"10.1016\/j.dsx.2024.103110","volume":"18","author":"MH Keivanlou","year":"2024","unstructured":"Keivanlou MH, Amini-Salehi E, Sattari N, Hashemi M, Saberian P, Prabhu SV, Javid M, Mirdamadi A, Heidarzad F, Bakhshi A, et al. Gut microbiota interventions in type 2 diabetes mellitus: an umbrella review of glycemic indices. DIABETES METAB SYND. 2024;18(8):103110.","journal-title":"DIABETES METAB SYND"},{"issue":"5","key":"3756_CR24","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1097\/MS9.0000000000001740","volume":"86","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Samethadka NS, Maddineni G, Mahapatro A, Keivanlou MH, Soltani MS, Vakilpour A, Aleali MS, Joukar F, Hashemi M, et al. Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials. ANN MED SURG. 2024;86(5):2900\u201310.","journal-title":"ANN MED SURG"},{"issue":"8","key":"3756_CR25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","volume":"76","author":"Z Safari","year":"2019","unstructured":"Safari Z, G\u00e9rard P. The links between the gut Microbiome and non-alcoholic fatty liver disease (NAFLD). CELL MOL LIFE SCI. 2019;76(8):1541\u201358.","journal-title":"CELL MOL LIFE SCI"},{"key":"3756_CR26","doi-asserted-by":"crossref","unstructured":"Moszak M, Szuli\u0144ska M, Walczak-Ga\u0142\u0119zewska M, Bogda\u0144ski P. Nutritional approach targeting gut microbiota in NAFLD-To date. Int J Environ Res Public Health 2021;18(4).","DOI":"10.3390\/ijerph18041616"},{"issue":"11","key":"3756_CR27","doi-asserted-by":"publisher","first-page":"e13316","DOI":"10.1111\/obr.13316","volume":"22","author":"S Zhang","year":"2021","unstructured":"Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Reviews: Official J Int Association Study Obes. 2021;22(11):e13316.","journal-title":"Obes Reviews: Official J Int Association Study Obes"},{"issue":"19","key":"3756_CR28","doi-asserted-by":"publisher","first-page":"9878","DOI":"10.1039\/D2FO01343F","volume":"13","author":"H Chen","year":"2022","unstructured":"Chen H, Sun Y, Zhao H, Qi X, Cui H, Li Q, Ma Y. \u03b1-Lactalbumin peptide Asp-Gln-Trp alleviates hepatic insulin resistance and modulates gut microbiota dysbiosis in high-fat diet-induced NAFLD mice. Food Funct. 2022;13(19):9878\u201392.","journal-title":"FOOD FUNCT"},{"key":"3756_CR29","doi-asserted-by":"crossref","unstructured":"Li J, Li Y, Feng S, He K, Guo L, Chen W, Wang M, Zhong L, Wu C, Peng X et al. Differential effects of dietary white meat and red meat on NAFLD progression by modulating gut microbiota and metabolites in rats. Oxid Med Cell Longev. 2022;2022:6908934.","DOI":"10.1155\/2022\/6908934"},{"key":"3756_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fmed.2020.00361","volume":"7","author":"X Jiang","year":"2020","unstructured":"Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the involvement of gut microbiota in pathophysiology of NAFLD. FRONT MED-LAUSANNE. 2020;7:361.","journal-title":"FRONT MED-LAUSANNE"},{"issue":"7","key":"3756_CR31","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","volume":"152","author":"O Ch\u00e1vez-Talavera","year":"2017","unstructured":"Ch\u00e1vez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152(7):1679\u201394.","journal-title":"Gastroenterology"},{"key":"3756_CR32","doi-asserted-by":"publisher","first-page":"908011","DOI":"10.3389\/fmicb.2022.908011","volume":"13","author":"Y Ni","year":"2022","unstructured":"Ni Y, Lu M, Xu Y, Wang Q, Gu X, Li Y, Zhuang T, Xia C, Zhang T, Gou X, et al. The role of gut Microbiota-Bile acids Axis in the progression of Non-alcoholic fatty liver disease. Front Microbiol. 2022;13:908011.","journal-title":"FRONT MICROBIOL"},{"key":"3756_CR33","doi-asserted-by":"crossref","unstructured":"Song Q, Zhang X. The Role of Gut-Liver Axis in Gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines 2022;10(3).","DOI":"10.3390\/biomedicines10030524"},{"key":"3756_CR34","doi-asserted-by":"crossref","unstructured":"Carpi RZ, Barbalho SM, Sloan KP, Laurindo LF, Gonzaga HF, Grippa PC, Zutin TLM, Girio RJS, Repetti CSF, Detregiachi CRP et al. The effects of probiotics, prebiotics and synbiotics in Non-Alcoholic fat liver disease (NAFLD) and Non-Alcoholic steatohepatitis (NASH): A systematic review. Int J Mol Sci 2022;23(15).","DOI":"10.3390\/ijms23158805"},{"key":"3756_CR35","doi-asserted-by":"crossref","unstructured":"Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci 2020;21(15).","DOI":"10.3390\/ijms21155214"},{"key":"3756_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fphar.2018.00533","volume":"9","author":"M Li","year":"2018","unstructured":"Li M, van Esch B, Henricks P, Folkerts G, Garssen J. The Anti-inflammatory effects of short chain fatty acids on Lipopolysaccharide- or tumor necrosis factor \u03b1-Stimulated endothelial cells via activation of GPR41\/43 and Inhibition of HDACs. FRONT PHARMACOL. 2018;9:533.","journal-title":"FRONT PHARMACOL"},{"key":"3756_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molmet.2018.01.005","volume":"9","author":"K Jadhav","year":"2018","unstructured":"Jadhav K, Xu Y, Xu Y, Li Y, Xu J, Zhu Y, Adorini L, Lee YK, Kasumov T, Yin L, et al. Reversal of metabolic disorders by Pharmacological activation of bile acid receptors TGR5 and FXR. MOL METAB. 2018;9:131\u201340.","journal-title":"MOL METAB"},{"issue":"8","key":"3756_CR38","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","volume":"33","author":"BL Clifford","year":"2021","unstructured":"Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC, Wahlstr\u00f6m A, Ashby JW, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. CELL METAB. 2021;33(8):1671\u201384.","journal-title":"CELL METAB"},{"key":"3756_CR39","doi-asserted-by":"crossref","unstructured":"Gottlieb A, Canbay A. Why bile acids are so important in Non-Alcoholic fatty liver disease (NAFLD) progression. Cells-Basel 2019; 8(11).","DOI":"10.3390\/cells8111358"},{"key":"3756_CR40","doi-asserted-by":"crossref","unstructured":"Theofilis P, Vordoni A, Kalaitzidis RG. Trimethylamine N-Oxide levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolites 2022;12(12).","DOI":"10.3390\/metabo12121243"},{"key":"3756_CR41","doi-asserted-by":"crossref","unstructured":"Feng D, Zhang H, Jiang X, Zou J, Li Q, Mai H, Su D, Ling W, Feng X. Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice. Environ Pollution (Barking Essex: 1987). 2020;265Pt A. 114880.","DOI":"10.1016\/j.envpol.2020.114880"},{"issue":"12","key":"3756_CR42","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1007\/s00253-020-10633-9","volume":"104","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Chen L, Zhao Y, Wang C, Duan C, Yang G, Niu C, Li S. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. APPL MICROBIOL BIOT. 2020;104(12):5273\u201382.","journal-title":"APPL MICROBIOL BIOT"},{"key":"3756_CR43","doi-asserted-by":"crossref","unstructured":"Telle-Hansen VH, Holven KB, Ulven SM. Impact of a Healthy Dietary Pattern on Gut Microbiota and Systemic Inflammation in Humans. NUTRIENTS 2018, 10(11).","DOI":"10.3390\/nu10111783"},{"issue":"7","key":"3756_CR44","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/gutjnl-2020-322670","volume":"70","author":"LA Bolte","year":"2021","unstructured":"Bolte LA, Vich VA, Imhann F, Collij V, Gacesa R, Peters V, Wijmenga C, Kurilshikov A, Campmans-Kuijpers M, Fu J, et al. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut Microbiome. Gut. 2021;70(7):1287\u201398.","journal-title":"Gut"},{"key":"3756_CR45","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Montes DOA, Juli\u00e1n MT, Ramos A, Puig-Domingo M, Alonso N. Microbiota, Fiber, and NAFLD: Is There Any Connection? Nutrients 2020;12(10).","DOI":"10.3390\/nu12103100"},{"key":"3756_CR46","doi-asserted-by":"crossref","unstructured":"Hinnig PDF, Monteiro JS, de Assis MAA, Levy RB, Peres MA, Perazi FM, Porporatti AL, Canto GDL. Dietary patterns of children and adolescents from high, medium and low human development countries and associated socioeconomic factors: A Systematic Review. Nutrients 2018;10(4).","DOI":"10.3390\/nu10040436"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03756-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03756-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T17:24:38Z","timestamp":1741800278000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03756-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3756"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03756-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available summary data, and ethics approval was not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all participants in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}